AU4281999A - Peptide - Google Patents

Peptide

Info

Publication number
AU4281999A
AU4281999A AU42819/99A AU4281999A AU4281999A AU 4281999 A AU4281999 A AU 4281999A AU 42819/99 A AU42819/99 A AU 42819/99A AU 4281999 A AU4281999 A AU 4281999A AU 4281999 A AU4281999 A AU 4281999A
Authority
AU
Australia
Prior art keywords
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42819/99A
Inventor
Patrick Harriott
John Nelson
Andrew Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812376.3A external-priority patent/GB9812376D0/en
Priority claimed from GBGB9814888.5A external-priority patent/GB9814888D0/en
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Publication of AU4281999A publication Critical patent/AU4281999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
AU42819/99A 1998-06-10 1999-06-10 Peptide Abandoned AU4281999A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9812376 1998-06-10
GBGB9812376.3A GB9812376D0 (en) 1998-06-10 1998-06-10
GBGB9814888.5A GB9814888D0 (en) 1998-07-10 1998-07-10
GB9814888 1998-07-10
PCT/GB1999/001848 WO1999064449A2 (en) 1998-06-10 1999-06-10 Cell-permeable peptide

Publications (1)

Publication Number Publication Date
AU4281999A true AU4281999A (en) 1999-12-30

Family

ID=26313825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42819/99A Abandoned AU4281999A (en) 1998-06-10 1999-06-10 Peptide

Country Status (3)

Country Link
EP (1) EP1086126A1 (en)
AU (1) AU4281999A (en)
WO (1) WO1999064449A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE419273T1 (en) * 1998-11-13 2009-01-15 Cyclacel Ltd TRANSLOCATION VECTORS DERIVED FROM THE ANTENNAPEDIA HOMEODOMAIN HELIX 3
ATE321782T1 (en) * 1999-09-27 2006-04-15 Elan Corp MEMBRANE-TRANSLOCING PEPTIDE AS A DRUG TRANSPORT SYSTEM
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
ES2293977T3 (en) * 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHOD FOR USE.
EP1862471A3 (en) * 2000-02-07 2008-05-28 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
FR2819514B1 (en) * 2001-01-12 2003-02-28 Rhobio ANTIMICROBIAL PSEUDOPEPTIDES
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2005060541A2 (en) 2003-12-01 2005-07-07 Wisconsin Alumni Research Foundation Peptides and methods for inducing cellular resistance to infection
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
DK2453923T3 (en) 2009-07-14 2016-02-15 Mayo Foundation Non-covalent peptide-FEED of active agents across the blood brain barrier
KR20150050646A (en) * 2013-10-29 2015-05-11 삼성전자주식회사 Fusion peptide and use thereof for cell membrane penetrating
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19526174C2 (en) * 1995-07-18 1998-02-26 Friedhelm Prof Dr Herrmann Anti-tumor growth agent

Also Published As

Publication number Publication date
WO1999064449A2 (en) 1999-12-16
EP1086126A1 (en) 2001-03-28
WO1999064449A3 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
AU2434199A (en) Protein
AU3485999A (en) Neo-tryptophan
AU1685600A (en) Polypeptides
AU9392998A (en) Pack-a-pillow
AU4281999A (en) Peptide
AU3522399A (en) Carvedilol-galenics
AU3437799A (en) City-car
GB9825854D0 (en) Peptide
AU4930399A (en) Novel Polypeptide
AU3253699A (en) Myxochelines
AU5407599A (en) Sphingolipid-desaturase
AU1999999A (en) Contryphan peptides
AU8363398A (en) Capotasto
AU2609599A (en) Sensor-coupling
AU3204999A (en) Futureball
AU2069199A (en) Codelets
AU1552800A (en) Coupled peptides
AU1184800A (en) Novel polypeptide
AU1055399A (en) Rollerboard
AU3347599A (en) Aeromobile
AU5223199A (en) Bathtub-bathseat
AU9347498A (en) Imidazotriazolopyrimidines
AU5446599A (en) Peptide compounds
AU3819799A (en) Methoximinomethyloxathiazines
AU2840799A (en) 1-phosphanorbornadienes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase